ENGLEWOOD, Colo., June 4, 2015 -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced week 20 and week 24 results of the STRIDE study, a phase III clinical trial to investigate the effect of AmpionTM – a low molecular weight filtrate of an FDA approved biologic – to treat pain due to osteoarthritis (OA) of the knee. OA is the most common form of arthritis and affects more than 27 million people in the United States alone.
The STRIDE study allowed inclusion of patients in all disease stages and demographics, which resulted in 67 percent of patients with severe disease (Kellgren-Lawrence 4) and greater body mass index than seen in comparable OA trials. Analysis of the STRIDE study results at week 20 showed an effect over baseline of 59 percent in K-L3 (p less than 0.001) and 31 percent (p less than 0.001) in K-L4 patients. That reduction in pain persisted and was not materially different at week 24.
"No approved therapy has been shown to be effective in relieving OA pain for the most severely affected patients, indicating a clear medical need," said Michael Macaluso, Chief Executive Officer. "Ampio remains committed to delivering a safe, innovative medicine, as evidenced by our continued progress towards regulatory filing."
The full Ampion™ data set will be included as part of the company's Integrated Summary of Effectiveness (ISE) – a comprehensive analysis that integrates trial data used for FDA submission. The ISE for Ampion™ includes OA patient data (moderate to severe) from the SPRING, STRUT and STRIDE trials. This data will include over 700 patients using the WOMAC A (pain scale) as their primary endpoint. Results show Ampion™ to have a statistically significant improvement over saline control (p equal to 0.03), despite the aberrant saline response in the STRIDE study.
Included in the ISE are results showing improved sleep, which has metabolic benefits for blood pressure, weight and depression. No drug-related serious adverse events in any Ampion™ Study.
The company will present the data to the FDA and, once regulatory guidance is received, provide detailed information through appropriate channels such as conferences and publications.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
Forward Looking Statements
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "plan," "continue", "present," "will be," and similar expressions. These forward-looking statements include statements regarding Ampio's plans with respect to the AmpionTMtrials, which are subject to therisks associated with clinical trials, regulatory approvals, and changes in business conditions and similar events. These risks include the uncertainty of the regulatory response to the sufficiency of trial data and trial design, that regulatory approval may not be obtained or delayed, and the risks and uncertainties detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.